PT  - JOURNAL ARTICLE
AU  - Cerqueira-Silva, Thiago
AU  - de Araújo Oliveira, Vinicius
AU  - Pescarini, Julia
AU  - Júnior, Juracy Bertoldo
AU  - Machado, Tales Mota
AU  - Ortiz, Renzo Flores
AU  - Penna, Gerson
AU  - Ichihara, Maria Yury
AU  - de Barros, Jacson Venâncio
AU  - Boaventura, Viviane S.
AU  - Barreto, Mauricio L.
AU  - Werneck, Guilherme Loureiro
AU  - Barral-Netto, Manoel
TI  - The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19)
AID  - 10.1101/2021.08.21.21261501
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.21.21261501
4099  - http://medrxiv.org/content/early/2021/08/25/2021.08.21.21261501.short
4100  - http://medrxiv.org/content/early/2021/08/25/2021.08.21.21261501.full
AB  - Background High rates of virus transmission and the presence of variants of concern can affect vaccine effectiveness (VE). Both conditions occur in low-income countries, which primarily use viral vector or inactivated virus vaccine technologies. However, few VE analyses have been conducted in such countries, and most lack the power to evaluate effectiveness in subgroups, such as the elderly.Methods The present retrospective cohort study evaluated the effectiveness of Vaxzevria and CoronaVac vaccines for COVID-19-related infection in 60,577,870 Brazilian vaccinees from January 18 to June 30, 2021.Study outcomes included documented infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Covid-19–related hospitalization, ICU admission and death. We estimated VE for each outcome as one minus the hazard ratio using Cox regression adjusted for age, sex, Brazilian deprivation index, and month/region of dose administration.Results Vaccination with Vaxzevria or CoronaVac was found to be effective against SARS-CoV-2 infection and highly effective against hospitalization, ICU admission and death in individuals up to 79 years. From 80-89 years of age, 91.2 (95CI: 89.1-92.9) VE against death was seen in Vaxzevria-vaccinated individuals versus 67.3 (95CI: 63.6-70.6) for Coronvac. Above 90 years, 70.5 (95CI: 51.4-82.1) protection was conferred to Vaxzevria-vaccinated individuals versus 35.4 (95CI: 23.8-45.1) in Coronavac-vaccinated individualsConclusions Both vaccines demonstrated overall effectiveness against severe COVID-19 up to 80 years of age. Our results suggest that individuals aged 90 years or older may benefit from an expedited third booster dose. Ongoing evaluations, including any additional vaccines authorized, are crucial to monitoring long-term vaccine effectiveness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFUNDING This study was partially supported by a donation from the "Fazer o bem faz bem"-JBS program. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Brazilian National Commission in Research Ethics approved the research protocol (CONEP approval number 4.921.308). The study was considered exempt from informed consent; no human health risks were identified. All work presented here used unidentified secondary data in accordance with the Brazilian Personal Data Protection General Law (LGPD). Data was manipulated in a secure computing environment, ensuring protection against data leakage and records reidentification.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe used third-party data, provided by the Brazilian Ministry of Health. Any request for access to the data shall be directed to DATASUS - Ministry of Health Brazil: https://datasus.saude.gov.br/ https://datasus.saude.gov.br/